BIIB34:BVMF
Biogen Inc BDR
230,10 BRL
0,00%
(0,00) 1D
4 nën, 3:38:07 m.d., GMT-3 · BRL
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për BIIB34...
Kapitalizimi i tregut
37,16 mld
Vëllimi mesatar
9,00
Vëllimi
0,00
Maksimumi 52-javor
230,10 BRL
Minimumi 52-javor
147,50 BRL
Aksionet në qarkullim
147,82 mln
Numri i punonjësve
8 mijë
Kapitalizimi i tregut
37,16 mld
Vëllimi mesatar
9,00
Vëllimi
0,00
Maksimumi 52-javor
230,10 BRL
Minimumi 52-javor
147,50 BRL
Aksionet në qarkullim
147,82 mln
Numri i punonjësve
8 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Investing.com
·
1 orë më parë
Needham reiterates Biogen stock rating on Alzheimer’s drug data
Yahoo Finance
·
1 orë më parë
Biogen (BIIB) After Fresh Alzheimer’s Data, Is The Valuation Story Still Compelling?
Yahoo Finance
·
15 orë më parë
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
Yahoo Finance
·
16 orë më parë
Biogen: 3 Key Takeaways for Long-Term Investors
Profili
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Rreth Biogen Inc BDR
Drejtori ekzekutivChris Viehbacher
Punonjësit7,5 mijë
Themeluar më1978
SeliaKembrixh, Massachusetts, Shtetet e Bashkuara të Amerikës
SektoriHealth Care
Industria-
Uebsajtibiogen.com